Melanie Klausner

To the editors, Multiple myeloma (MM) is a genetically heterogeneous plasma cell malignancy in which cytogenetic abnormalities are central to risk stratification and treatment decisions. 17p loss, 1p loss, 1q gain/amplification, and IGH rearrangements define high-risk disease [1, 2].

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.